Key Highlights

  • Adjusted diluted EPS of USD 2.66 beat the consensus estimate of USD 2.20 and rose 35.7% from last year.
  • Net sales of USD 874.5 million rose 8.7%, topping the consensus estimate of USD 827.12 million, on 11.9% organic growth.
  • High-Value Product Components sales reached USD 466.7 million, up 19.7% and representing 53% of total company net sales.
  • Full year adjusted EPS guidance rose to USD 9.38 to USD 9.48 from USD 8.85 to USD 9.05.

West Pharmaceutical Services, Inc. (NYSE:WST) reported third quarter 2026 adjusted Diluted Earnings per Share of USD 2.66, above a consensus estimate of USD 2.20 and up from USD 1.96 a year earlier. GAAP diluted EPS was USD 3.02 versus USD 1.92, lifted by a pre-tax benefit of USD 54.0 million from M&A activities, including the sale of the SmartDose 3.5mL product line. Net sales were USD 874.5 million, ahead of a consensus estimate of USD 827.12 million and up from USD 804.6 million.

Mix Shift Lifts Margins

Proprietary Products net sales rose 12.6% to USD 728.8 million, or 16.6% organically. High-Value Product Components grew 20.3% organically, with the chief financial officer citing biologics, GLP-1 Demand and a favorable mix shift. GLP-1 related components represented just under 12% of total revenue. High-Value Product Delivery Devices sales of USD 99.1 million were flat, or up 26.4% organically excluding currency and the SmartDose 3.5mL divestiture. West Vantage sales fell 7.3% to USD 145.7 million as a continuous glucose monitoring program rolled off.

Gross Margin widened to 39.7% from 36.6%, and adjusted Operating Margin rose to 25.3% from 21.1%, a gain of 420 basis points. Reported operating profit was USD 267.4 million versus USD 167.6 million, while adjusted operating profit was USD 221.5 million versus USD 170.1 million. The adjusted tax rate came in at 17%. Chief Executive Officer Michel Lagarde, who joined West two months before the call, said results were led by the High-Value Product Components business.

Guidance and Capital Returns

Full year net sales guidance rose to USD 3.41 billion to USD 3.42 billion from USD 3.345 billion to USD 3.380 billion, with organic growth guided to 11.3% to 11.6%. Adjusted EPS guidance of USD 9.38 to USD 9.48 represents growth of 29% to 30%. Capital spending guidance was lowered to USD 215 million to USD 220 million from USD 250 million to USD 275 million. Management projects full year operating margin expansion of almost 300 basis points.

The company repurchased USD 231 million of stock in the quarter and USD 685 million year to date. The board declared a fourth quarter Dividend of USD 0.26 per share, up 18% from USD 0.22. Year to date Operating Cash Flow was USD 403 million, and the company upsized its revolving Credit Facility to USD 750 million with a five year renewal.

Signposts for the Fourth Quarter and 2027

Fourth quarter net sales are implied at USD 820 million to USD 830 million, or 6% to 7% organic growth, with double-digit High-Value Product Components growth anticipated by management. The company said Asia Pacific, about 11% of revenue, grew 42%, and Americas grew 12% while EMEA grew 6%.

For next year, management said SmartDose 3.5mL Revenue of about USD 100 million in 2026 is excluded from organic growth but creates a roughly 290 basis point headwind to reported growth. Full 2027 guidance is scheduled for the fourth quarter call in February. Free cash flow for nine months was USD 278 million, roughly 5% lower than a year earlier, and the company added over 200 upgrade projects this year.